

## Heart failure

Is a progressive clinical syndrome associated with impairment of the ability of the ventricle to fill with (diastolic ) or eject blood (systolic).

- Coronary artery disease and HTN are the leading cause of HF.


### HF with reduced ejection fraction (HFrEF)

- There is decrease in cardiac output , result in activation of compensatory response to maintain adequate CO
- Compensation done by : activation of SNS and RAAS result in vasoconstriction , Na and water retention , ventricular hypertrophy and remodeling.
- Causes of systolic dysfunction: MI , dilated cardiomyopathy , ventricular hypertrophy , pressure overload(syst. Or pulmo. HTN , aortic or pulmo valve stenosis), volume overload (valve regurg. , shunt , high output state.

### HF with preserved ejection fraction(HFpEF)

- Is primarily due to diastolic dysfunction of the heart (disturbances in relaxation )
- Causes : MI , ventricular hypertrophy , increase in ventricular stiffness , infiltrative myocardopathy ( amyloidosis , sarcoidosis , fibrosis ) , mitral or tricuspid valve stenosis , pericardial disease ( pericarditis , tamponade )

- Means : changes in both myocardial cells and extracellular matrix resulting in changes in ventricular SHAPE (from ellipse to sphere) , SIZE , STRUCTURE, FUNCTION.
- Changes in size and shape will further depress the mechanical performance of the heart and sustain progression of remodeling.
- Angiotensin 2 , NE , endothelin , aldosterone , vasopressin and inflammatory cytokines play an imp. role in initiating signal transduction cascade responsible for remodeling and are toxic to other organs, so HF is a systemic and cardiac disease.



#### **\*EXAMPLE ON DRUGS :**

##### **- Negative inotropic effect :**

- 1) Antiarrhythmics (disopyramide , flecainide,propafenone)
- 2)Beta blockers (propranolol , metoprolol , carvedilol)
- 3)CCB (verapamil , diltiazem)

##### **-Cardiotoxicity:**

Doxorubicin , epirubicin , daunomycin , ethanol , cyclophosphamide , trastuzumab , bevacizumab , ifosfamide , lapatinib , sunitinib , imatinib , amphetamine , cocaine.

##### **-Sodium and water retention:**

NSAID , cox2 inhibitor , rosiglitazone , pioglitazone , steroid , androgen&estrogen , high dose salicylate , high Na containing drug (ticarcillin disodium).

.....

## **Therapy of CHRONIC HF**

**GOALS OF Tx :** Improve quality of life , relieve symptoms , prevent or minimize hospitalization , slow progression of the disease , prolong survival .

**General measures in Tx :** Accurate diagnosis , identification and Tx of risk factors , elimination the precipitating factors , appropriate pharmacologic and nonpharmacologic therapy , close monitoring and follow-up.

**\*Note :** Tx of HFrEF is based on numerous large , randomized , double-blind , multicenter clinical trials , while HFpEF based on studies in relatively small groups of patients and on clinical experience.

**Things you do before giving medication :** determine the cause , treat the underlying disease , revascularization or anti-ischemic in pt with CHD , stop drugs that aggravate HF , restriction of physical activity in pt with acute congestive symptoms but after stabilization you have to advice the pt to do physical exercise , restriction of Na and water intake .

patient with hyponatremia  $<130$  or with persistent volume retention despite high diuretic doses and Na restriction should limit fluid intake to 2 L/DAY.  
 Be careful with na and water restriction in pt with HFpEF because there is risk of hypotension , low output state and renal insufficiency .  
 .....

Tx OF **HFpEF**: control HR&BP, alleviate causes of MI, reduce volume, maintain sinus rhythm.

#### Symptoms targeted tx :

- Decrease pulmo. Venous pressure to reduce left ventricular volume by : diuretics , nitrate , salt restriction.
- Reduce o2 demand to reduce HR&BP by : b blocker , ccb (verapamil,diltiazem),ACEI , ARB.
- Maintain atrial contraction to restore sinus rhythm by : cardioversion of A.Fib
- Improve exercise tolerance by using positive inotropic agent.

#### Disease targeted tx :

- Prevent or treat MI by : b blocker , nitrate , verapamil and diltiazem.
- Prevent or regress ventricular hypertrophy by antihypertensive drugs.

#### Mechanism targeted tx :

- Modify myocardial and extramyocardial mechanism by diuretics , ACEI, ARB , spironolactone.
- Modify intracellular and extracellular mechanism by diuretics , ACEI , ARB.

#### Some NOTES about HFpEF medications:

##### Diuretics :

- \*Loop or thiazide can be used.
- \*Do not reduce preload excessively , this will reduce stroke volume and CO.
- \*Aldosterone antagonist can be used if there is no risk of hyperkalemia or other contraindication.

##### ACE inhibitor :

- \*used in all pt with atherosclerotic cardiovascular disease or DM.
- \*ARB is alternative if patient develops cough or angioedema.


##### B-blocker :

- \*should be considered if pt has one or more :

  - 1) MI
  - 2) HTN
  - 3) A.Fib

##### CCB :

- \*verapamil or diltiazem.
- \*used in pt with A.Fib who is not responded to b-blocker.
- \*nondihydropyridine or dihydropyridine can be used for angina & HTN.



Tx OF HFrEF (stage A,B,C,D)

#### Stage A :

- Treat the risk factors (HTN,DM,SMOKING ,dyslipidemia)  
\*risk factors act synergistically to develop HFREF&HFPEF
- ACE I OR ARB & STATINS are imp to prevent HF in pt with cardiovascular risk factors.

#### Stage B :

- They have structural heart disease without HF symptoms , so the aim of tx is minimize remodeling process.
- No Hx of MI : ACE I OR ARB & B-blocker.
- WITH HX of MI : ACE I OR ARB & evidence based b blocker & statin .

#### Stage C :

- Patient with structural disease and symptoms .
- ACE I OR ARB & evidence based b blocker ; to slow HF progression , reduce morbidity&mortality , improve symptoms.
- LOOP diuretics , aldosterone antag. , hydralazine-isosorbide dinitrate.
- Digoxin in selected pt (ivabradine , sacubitril/valsartan).
- ICD , CRT , Biventricular pacemaker can be used.

#### Stage D :

- Is advanced,refractory or end stage HF.
- Special therapy : mechanical circulatory support , continuous IV positive inotrope , cardiac transplantation &Tx in stage A-C.
- Restriction of Na and fluid , high doses of diuretics(loop&thiazide) , ultrafiltration to remove excess fluid. NOTE : those pt may be less tolerant to ACEi (hypotension,worsen renal insufficiency) , b-blocker (worsen HF) , so starting with low doses , slow upward titration and close monitoring are imp.

Medications	HFpEF	HFrEF
B-BLOCKER	Decrease HR , prolong diastole , modify hemodynamic response to exercise.	Improve the inotropic state and modify LV remodeling.
DIURETICS	Doses are much smaller than →	
CCB	Improve exercise capacity , treat HTN&CAD , they lower HR.	Should be avoided

## Some NOTES about HFrEF medication :

### Diuretics

- Benefits : reduce symptoms associated with fluid retention / improve exercise tolerance & quality of life / reduce hospitalization / reduce pulmo&peripheral edema through reduction of preload .
- They do not prolong survival .
- Risks : over-diuresis lead to hypotension and renal injury specially in pt with ACE I OR B-BLOCKER.
- Hypotension more common in HFpEF ; small change in volume causes large change in filling pressure and cardiac output.
- Thiazide or thiazide like diuretics (metolazone,indapamide) can be used with loop diuretics in pt with mild fluid retention.
- Loop are imp to restore and maintain euvolemia , they induce prostaglandin-mediated increase in renal blood flow, so coadministration of NSAID with diminish diuretic efficacy.
- Unlike thiazide , loop can be used even in impaired renal function.

### B-BLOCKER (carvedilol, metoprolol succinate ,bisoprolol)

- They decrease ventricular mass , improve the sphericity of V , decrease systolic& diastolic volume; all these are called Reverse Remodeling.
- Used in all **stable** patient with mild or well controlled symptoms .
- Also , used in asymptomatic pt with low EF , to decrease the progression .
- B-blocker are used after giving ACEi , because there is risk of decompensation if they are used first.
- Patient with tachycardia or K concentration preclude due to ACEi , may benefit from initiating b blocker.
- DO NOT USE B-BLOCKER IN PT WITH IV INOTROPIC SUPPORT.
- VERY IMP to give HFpEF b-blocker ; they cant tolerate tachycardia and may promote ischemia due to increase in o2 demand , but be careful not to induce excessive bradycardia because they decrease cardiac output.

### ACE I

- They attenuate ventricular remodeling , myocardial fibrosis , apoptosis , cardiac hypertrophy , NE release , vasoconstriction , Na & water retention , lower glomerular capillary pressure.
- Bradykinin is increased due to the release of histamine & prostaglandin.
- Captopril , ramipril , trandolapril are used in post – MI pt.
- Monitoring is imp ; there is risk of worsening renal function and/or hyperkalemia.
- They improve survival 20-30%.

### ARB (candesartan,losartan,valsartan)

- Attenuate ventricular remodeling .
- No release OF bradykinin , so they're used in pt who can't tolerate cough&edema from ACEi
- Angiotensin 2 can be formed in many tissues including heart through pathways (chymase ,cathepsin ,kallikrein.

### Aldosteron antagonist

- Spironolactone , eplerenone
- they have potassium sparing effect , attenuate atherogenesis , oxidative stress cause by aldosterone.
- attenuate cardiac fibrosis by inhibiting cardiac extracellular matrix and collagen deposition.
- spironolactone decrease mortality 30% , they cause gynecomastia & hyperkalemia.
- eplerenone decrease mortality 15% , it causes hyperkalemia.
- people more susceptible to develop hyperkalemia : impaired renal function / fail to decrease k supplement / DM / high k food intake / use ACEI , ARB , NSAID .
- things you do to decrease risk of hyperkalemia:
  - 1)Avoid starting in female with Cr >2 and male >2.5 or CrCL<30 , pt with worsen renal function, serum k >5 , Hx of hyperkalemia .
  - 2)start with low dose & stop k supplement
  - 3)avoid NSAID,ACEI,ARB , high k food
  - 4)monitor serum k weekly then monthly , if it exceeds 5.5 mg/dl , reduce or stop the drug.

## Drug therapy for selected patient with HFrEF

### Nitrate & Hydralazine (combination)

- If there is contraindication for using ACEI/ARB then give NITRATE (venodilator , decrease preload) & HYDRALAZINE (vasodilator , decrease afterload).
- Hydralazine reduces oxidative stress & mortality .
- Nitrate attenuate myocardial remodeling , reduce cardiac hypertrophy ,dilation and mortality.
- combination is important , 3 times daily
- It provides limited benefit to patients with HFpEF unless they have angina , they will benefit from nitrate.

### ARB/Neprilysin inhibitor (fixed dose combination)

- Neprilysin is a zinc dependant metalloprotease that break down the natriuretic peptides ANP & BNP bradykinin , it causes vasodilation , natriuresis and diuresis **if** you inhibit it by medication called **Sacubitril**.

### Valsartan / Sacubitril (combination)

- useful in HFrEF
- Side effect : hypotension , dizziness , hyperkalemia , cough , angioedema .
- Drug interaction : don't use with ACEI , ARB , Aliskiren (direct renin inhibitor).
- CONTRAINDICATION (Hx of angioedema , pregnancy , hyperkalemia , renal artery stenosis , severe hepatic impairment , renal dysfunction , diabetic pt taking aliskiren).

### Ivabradine

- It controls the heart rate and slows the spontaneous depolarization of SA node .
- ONLY 2 indication for this drug :
  - 1) patient with HFrEF & HR > 70 that is receiving max. tolerated Tx with B-BLOCKER
  - 2) " " " " with contraindication to B-BLOCKER.
- Is metabolized by CYP3A4 , so avoid taking it with CYP3A4 inhibitors (itraconazole , macrolide , hiv protease inhibitor , verapamil , diltiazem , grapefruit juice )
- AVOID taking it with CYP3A4 inducers (St.Johns wort , rifampin , phenytoin)
- Side effect : QT prolongation , bradycardia , effect on vision (transient brightness) , atrial fibrillation.

### Digoxin

- Is positive inotropic drug , improves cardiac function , no benefit on mortality or hospitalization .
- No benefit in HFpEF with normal sinus rhythm , but pt with HFpEF&A.Fib may benefit .
- is not a first line agent in HF.

Please read slides from 80-88  
The doctor didn't explain them , he  
said just read them .  
Thank you <3